Regeneron Pharmaceuticals (REGN) Current Assets (2009 - 2026)

Regeneron Pharmaceuticals' Current Assets history runs 18 years deep, the most recent figure standing at $18.2 billion for Q1 2026.

• In Q1 2026, Current Assets rose 3.63% year-over-year to $18.2 billion; the TTM figure through Mar 2026 stood at $18.2 billion (up 3.63% YoY), while the FY2025 annual figure was $18.0 billion, down 3.42% from the prior year.
• Current Assets was $18.2 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $18.0 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $19.5 billion in Q4 2023 to a low of $14.3 billion in Q1 2022.
• Historically, Current Assets has averaged $17.5 billion across 5 years, with a median of $18.0 billion in 2025.
• The sharpest annual moves came in 2022 and 2025: Current Assets surged 42.28% in 2022, then decreased 11.65% in 2025.
• A 5-year view of Current Assets shows it stood at $15.9 billion in 2022, then gained by 22.63% to $19.5 billion in 2023, then slipped by 4.2% to $18.7 billion in 2024, then declined by 3.42% to $18.0 billion in 2025, then rose by 1.04% to $18.2 billion in 2026.
• The last three Current Assets figures came in at $18.2 billion (Q1 2026), $18.0 billion (Q4 2025), and $18.0 billion (Q3 2025), per Business Quant data.